Cargando…
1001. Feasibility and Outcomes of a Pre-Transplant Antibiotic Allergy Evaluation Program for Allogeneic Hematopoietic Cell Transplant (HCT) Candidates
BACKGROUND: Antibiotic allergies impact the management of hematopoietic cell transplant (HCT) patients who are often prescribed antibiotics for infection prophylaxis and treatment. We evaluated the feasibility and outcomes of an antibiotic allergy evaluation program prior to allogeneic HCT. METHODS:...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811251/ http://dx.doi.org/10.1093/ofid/ofz360.865 |
_version_ | 1783462436542611456 |
---|---|
author | Liu, Catherine Krantz, Elizabeth M Stohs, Erica J Imlay, Hannah Rampur, Lahari Sweet, Ania Zier, Jacqlynn C Pergam, Steven A Mielcarek, Marco Henderson, William Altman, Matthew |
author_facet | Liu, Catherine Krantz, Elizabeth M Stohs, Erica J Imlay, Hannah Rampur, Lahari Sweet, Ania Zier, Jacqlynn C Pergam, Steven A Mielcarek, Marco Henderson, William Altman, Matthew |
author_sort | Liu, Catherine |
collection | PubMed |
description | BACKGROUND: Antibiotic allergies impact the management of hematopoietic cell transplant (HCT) patients who are often prescribed antibiotics for infection prophylaxis and treatment. We evaluated the feasibility and outcomes of an antibiotic allergy evaluation program prior to allogeneic HCT. METHODS: In August 2017, we implemented a program to expedite allergy clinic referrals for adult allogeneic HCT candidates who reported an antibiotic allergy at their initial pre-transplant evaluation visit (PTEV). Allergy labels and clinical data including outcomes of allergy evaluation were prospectively collected for patients with PTEVs between 8/10/17 and November 15/18. The use of selected antibiotics was collected in the 100 days following HCT among patients with a reported β-lactam allergy (BLA). Choice of prophylactic agent for Pneumocystis jiroveci among patients with reported sulfa allergies was assessed among HCT recipients after engraftment. RESULTS: Of 276 allogeneic HCT candidates, 109 (39.5%) reported >= 1 antibiotic allergy (Table 1). Of the 109, 69 (63%) were referred for allergy evaluation; 83% (57/69) of those referred were evaluated at a median of 14 days after PTEV, and a median of 18 days before transplant. Among evaluated patients, 45 (79%) had >= 1 antibiotic allergy de-labeled including 74% (28/38) of those with BLA (Figure 1). Of the 10 patients whose BLAs could not be delabeled, 1 had a possible immediate IgE-mediated reaction, 5 had a delayed type IV hypersensitivity, and 4 had other reactions or required additional testing. Post-transplant antibiotic use among evaluated vs. nonevaluated patients reporting BLA is shown in Figure 2. Among 31 patients with reported sulfa allergies who underwent HCT, those who were evaluated received TMP-SMX rather than alternative prophylaxis more often (48%; 11/23) than those who were not evaluated (25%; 2/8). 10 (43%) of 23 evaluated patients were delabeled; 7 of 10 delabeled patients received TMP-SMX. CONCLUSION: Antibiotic allergies are frequently reported among HCT candidates. Pre-transplant antibiotic allergy evaluation was feasible, led to de-labeling of the majority of reported allergies, and may alter antibiotic prescribing and increase the use of preferred agents following transplant. [Image: see text] [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures. |
format | Online Article Text |
id | pubmed-6811251 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-68112512019-10-29 1001. Feasibility and Outcomes of a Pre-Transplant Antibiotic Allergy Evaluation Program for Allogeneic Hematopoietic Cell Transplant (HCT) Candidates Liu, Catherine Krantz, Elizabeth M Stohs, Erica J Imlay, Hannah Rampur, Lahari Sweet, Ania Zier, Jacqlynn C Pergam, Steven A Mielcarek, Marco Henderson, William Altman, Matthew Open Forum Infect Dis Abstracts BACKGROUND: Antibiotic allergies impact the management of hematopoietic cell transplant (HCT) patients who are often prescribed antibiotics for infection prophylaxis and treatment. We evaluated the feasibility and outcomes of an antibiotic allergy evaluation program prior to allogeneic HCT. METHODS: In August 2017, we implemented a program to expedite allergy clinic referrals for adult allogeneic HCT candidates who reported an antibiotic allergy at their initial pre-transplant evaluation visit (PTEV). Allergy labels and clinical data including outcomes of allergy evaluation were prospectively collected for patients with PTEVs between 8/10/17 and November 15/18. The use of selected antibiotics was collected in the 100 days following HCT among patients with a reported β-lactam allergy (BLA). Choice of prophylactic agent for Pneumocystis jiroveci among patients with reported sulfa allergies was assessed among HCT recipients after engraftment. RESULTS: Of 276 allogeneic HCT candidates, 109 (39.5%) reported >= 1 antibiotic allergy (Table 1). Of the 109, 69 (63%) were referred for allergy evaluation; 83% (57/69) of those referred were evaluated at a median of 14 days after PTEV, and a median of 18 days before transplant. Among evaluated patients, 45 (79%) had >= 1 antibiotic allergy de-labeled including 74% (28/38) of those with BLA (Figure 1). Of the 10 patients whose BLAs could not be delabeled, 1 had a possible immediate IgE-mediated reaction, 5 had a delayed type IV hypersensitivity, and 4 had other reactions or required additional testing. Post-transplant antibiotic use among evaluated vs. nonevaluated patients reporting BLA is shown in Figure 2. Among 31 patients with reported sulfa allergies who underwent HCT, those who were evaluated received TMP-SMX rather than alternative prophylaxis more often (48%; 11/23) than those who were not evaluated (25%; 2/8). 10 (43%) of 23 evaluated patients were delabeled; 7 of 10 delabeled patients received TMP-SMX. CONCLUSION: Antibiotic allergies are frequently reported among HCT candidates. Pre-transplant antibiotic allergy evaluation was feasible, led to de-labeling of the majority of reported allergies, and may alter antibiotic prescribing and increase the use of preferred agents following transplant. [Image: see text] [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6811251/ http://dx.doi.org/10.1093/ofid/ofz360.865 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts Liu, Catherine Krantz, Elizabeth M Stohs, Erica J Imlay, Hannah Rampur, Lahari Sweet, Ania Zier, Jacqlynn C Pergam, Steven A Mielcarek, Marco Henderson, William Altman, Matthew 1001. Feasibility and Outcomes of a Pre-Transplant Antibiotic Allergy Evaluation Program for Allogeneic Hematopoietic Cell Transplant (HCT) Candidates |
title | 1001. Feasibility and Outcomes of a Pre-Transplant Antibiotic Allergy Evaluation Program for Allogeneic Hematopoietic Cell Transplant (HCT) Candidates |
title_full | 1001. Feasibility and Outcomes of a Pre-Transplant Antibiotic Allergy Evaluation Program for Allogeneic Hematopoietic Cell Transplant (HCT) Candidates |
title_fullStr | 1001. Feasibility and Outcomes of a Pre-Transplant Antibiotic Allergy Evaluation Program for Allogeneic Hematopoietic Cell Transplant (HCT) Candidates |
title_full_unstemmed | 1001. Feasibility and Outcomes of a Pre-Transplant Antibiotic Allergy Evaluation Program for Allogeneic Hematopoietic Cell Transplant (HCT) Candidates |
title_short | 1001. Feasibility and Outcomes of a Pre-Transplant Antibiotic Allergy Evaluation Program for Allogeneic Hematopoietic Cell Transplant (HCT) Candidates |
title_sort | 1001. feasibility and outcomes of a pre-transplant antibiotic allergy evaluation program for allogeneic hematopoietic cell transplant (hct) candidates |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811251/ http://dx.doi.org/10.1093/ofid/ofz360.865 |
work_keys_str_mv | AT liucatherine 1001feasibilityandoutcomesofapretransplantantibioticallergyevaluationprogramforallogeneichematopoieticcelltransplanthctcandidates AT krantzelizabethm 1001feasibilityandoutcomesofapretransplantantibioticallergyevaluationprogramforallogeneichematopoieticcelltransplanthctcandidates AT stohsericaj 1001feasibilityandoutcomesofapretransplantantibioticallergyevaluationprogramforallogeneichematopoieticcelltransplanthctcandidates AT imlayhannah 1001feasibilityandoutcomesofapretransplantantibioticallergyevaluationprogramforallogeneichematopoieticcelltransplanthctcandidates AT rampurlahari 1001feasibilityandoutcomesofapretransplantantibioticallergyevaluationprogramforallogeneichematopoieticcelltransplanthctcandidates AT sweetania 1001feasibilityandoutcomesofapretransplantantibioticallergyevaluationprogramforallogeneichematopoieticcelltransplanthctcandidates AT zierjacqlynnc 1001feasibilityandoutcomesofapretransplantantibioticallergyevaluationprogramforallogeneichematopoieticcelltransplanthctcandidates AT pergamstevena 1001feasibilityandoutcomesofapretransplantantibioticallergyevaluationprogramforallogeneichematopoieticcelltransplanthctcandidates AT mielcarekmarco 1001feasibilityandoutcomesofapretransplantantibioticallergyevaluationprogramforallogeneichematopoieticcelltransplanthctcandidates AT hendersonwilliam 1001feasibilityandoutcomesofapretransplantantibioticallergyevaluationprogramforallogeneichematopoieticcelltransplanthctcandidates AT altmanmatthew 1001feasibilityandoutcomesofapretransplantantibioticallergyevaluationprogramforallogeneichematopoieticcelltransplanthctcandidates |